BEI
RXRX icon

Benjamin Edwards Inc’s Recursion Pharmaceuticals RXRX Stock Holding History

Benjamin Edwards Inc’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$444K Sell
144,652
-2,137
-1% -$8.26K ﹤0.01% 1041
2025
Q4 		$600K Buy
146,789
+3,625
+3% +$18K 0.01% 891
2025
Q3 		$699K Sell
143,164
-21,612
-13% -$113K 0.01% 813
2025
Q2 		$834K Sell
164,776
-6,051
-4% -$29.7K 0.01% 691
2025
Q1 		$904K Buy
170,827
+11,833
+7% +$86.3K 0.01% 607
2024
Q4 		$1.07M Sell
158,994
-3,487
-2% -$23.4K 0.02% 587
2024
Q3 		$1.07M Buy
162,481
+161,259
+13,196% +$1.16M 0.02% 582
2024
Q2 		$9K Sell
1,222
-465
-28% -$4.06K ﹤0.01% 626
2024
Q1 		$17K Buy
1,687
+608
+56% +$6.77K ﹤0.01% 595
2023
Q4 		$11K Buy
+1,079
New +$7.69K ﹤0.01% 582

Other funds holding RXRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return